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 Synthesis of D-glucals attached by a C-1eC bond to each isomeric oxadiazole.
 Formation of 1,2-double bonds by DBU induced elimination.
 Formation of 1,2-double bonds by Zn/N-methylimidazole mediated reductive elimination.
 No inhibition of rabbit muscle glycogen phosphorylase b.
http://dx.doi.org/10.1016/j.carres.2015.04.016
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Synthetic methods were elaborated for D-glucals attached to oxadiazoles by a CeC bond. Introduction of
the double bond was effected by either DBU induced elimination of PhCOOH from the O-perbenzoylated
glucopyranosyl precursors or Zn/N-methylimidazole mediated reductive elimination from the 1-
bromoglucopyranosyl starting compounds. Alternatively, heterocyclizations of 2-deoxy-D-arabino-hex-
1-enopyranosyl cyanide were also carried out. Test compounds were obtained by Zemplen debenzoy-
lation, however, none of them showed signiﬁcant inhibition of rabbit muscle glycogen phosphorylase b.























The continuous interest in glycogen phosphorylase inhibitors
(GPIs) is primarily derived from the antihyperglycemic potential of
such molecules involving their possible application in the medi-
cation of patients with type II diabetes.1 On the other hand, inhi-
bition of glycogen phosphorylase (GP) enzymes has also become an
investigational approach in the context of other diseases such as
ischemic lesions2e5 and tumors.6e10
The inhibitors targeting the seven binding sites of GP (catalytic,
inhibitor, allosteric, new allosteric, glycogen storage, benzimid-
azole11 and the recently discovered quercetin binding site12) showa
large molecular diversity.13e17 Among them various glucose de-
rivatives bind mostly to the catalytic site of the enzyme.18,19 At
present, N-acyl-b-D-glucopyranosylamines, N-acyl-N0-b-D-gluco-
pyranosyl ureas, glucopyranosylidene-spiro-heterocycles as well as
N- and C-glucosylated heterocycles (see Chart 1 for some important
representatives of the latter e.g., 1e7, 13e20) belong to the most






inhibitors, Carbohydrate Resebelow the low micromolar range against rabbit muscle GPb
(RMGPb).17e19 X-ray crystallographic studies on the binding modes
of several of these molecules elucidated their increased binding
strengths in comparison to that of D-glucose (Ki¼1.7 and 7.4 mM for
the a and b anomers,20 respectively). Besides the ideal ﬁt of the
glucose part of these inhibitors in the active site, the strong binding
must be ascribed to the H-bonding capacities of the aglycons as
well as van der Waals interactions of an aromatic appendage (if
present) in the so-called b-channel of the enzyme.13 These ﬁndings
highlight the decisive contribution of the aglycon to the good in-
hibition and account for the fact that the structure-based inhibitor
design of glucose analog GPIs has mainly been focused on the
anomeric substitution patterns. Nevertheless, to get a thorough
insight into the structure-activity relationships, the exploration of
the speciﬁcity of the sugar unit is also necessary. Early in-
vestigations on the inhibitory and binding properties of different
monosaccharides indicated the superior effectiveness of D-
glucose.21,22 Changes in the sugar conﬁguration (e.g., for D-
mannose21 Ki>100 mM against RMGPb) as well as removal or
replacement of substituents of the glucose moiety (e.g., for 2-
deoxy-D-glucose21 Ki¼27 mM, for D-xylose21 Ki¼> 100 mM, for 3-
deoxy-3-ﬂuoro-D-glucose22 Ki¼200 mM against RMGPb) proved117
118
119
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Chart 1. Inhibitory potency (Ki [mM]) of selected N- and C-glycosyl heterocycles against rabbit muscle glycogen phosphorylase b (RMGPb).36, 37, 38, 42, 44 Q1



































































































































CAR6993_proof ■ 7 May 2015 ■ 2/9detrimental for the inhibition. Taking into account the crucial role
of the aglycon in the efﬁciency of the glucose based inhibitors al-
terations of the sugar moiety in cases of some potent heterocyclic
glucose derivatives were also examined to test whether the in-
teractions of the anomeric substituent could compensate the
impaired binding afﬁnity of the glycon.
As part of this program D-xylose derived analogs of the best
glucose based inhibitors were most often studied.
Xylopyranosylidene-spiro-hydantoins, the ﬁrst compounds inves-
tigated in this series, proved practically inactive.23
Xylopyranosylidene-spiro-isoxazolines and oxathiazoles,24 having
the most potent aglycones of the glucopyranosyl series,25e27
remained also ineffective.24 Xylopyranosyl counterparts of N-(b-D-
glucopyranosyl)-1,2,3-triazoles (e.g., 8 in Chart 1) as well as anal-
ogous derivatives of 5-thio-xylose and their oxidized variants
(sulfoxides and sulfones) showed also negligible or no inhibition
against RMGPb.28 Very recently, C-b-D-xylopyranosyl-heterocycles
were synthesized (e.g., 21 and 22), and among them only the 2-
naphthyl substituted 1,2,4-triazole derivative 21 had modest ac-
tivity towards RMGPb.24
Other studies with N-b-D-glucopyranosyl-pyrimidines15,17 2e7
and 9e12 showed that replacement of the 3-OH group of thePlease cite this article in press as: Bokor E, et al., C-(2-Deoxy-D-arabino-
their evaluation as glycogen phosphorylase inhibitors, Carbohydrate Resglucosemoiety by ﬂuorine caused very signiﬁcant weakening of the
inhibitions (see Chart 1 for the directly comparable pairs 2 and 9, 3
and 10, and 7 and 11, respectively).29 Nevertheless, elongation of
the aglycon by a hydrophobic group proved advantageous
(compare 11 and 12) rendering compound 12 to be the ﬁrst
micromolar inhibitor of this class.29 Furthermore, insertion of an
axially oriented hydroxymethyl group into the C-3 position of the
glucose part of 2 induced a slightly decreased inhibition
(Ki¼27.1 mM against RMGPb) in spite of additional molecular in-
teractions of the eCH2OH group that was evidenced by X-ray
crystallography.30
Additionally, in the frame of a study of conformationally
restricted pseudonucleosides, an N-substituted spiro-
thiohydantoin ring was constructed at the C-3 position of D-
glucose, however, such compounds remained inactive against
RMGPb.31 Glucofuranosylidene-spiro-hydantoins32 as well as some
iminosugar derivatives were also studied to show no signiﬁcant
activity except 1,4-dideoxy-1,4-imino-arabinitol (DAB).33
The phosphorolytic cleavage of glycogen catalyzed by GP is
supposed to occur via a glycosyliumion-like transition sate.34 Thus,
it can be expected that compounds known to be mimics of this
intermediate can bind to the active site of the enzyme as evidencedhex-1-enopyranosyl)-oxadiazoles: synthesis of possible isomers and
earch (2015), http://dx.doi.org/10.1016/j.carres.2015.04.016
Scheme 1. Reagents and conditions: a) DBU, dry CH2Cl2, rt; b) Zn, N-methylimidazole, dry EtOAc, reﬂux; c) NH2OH$HCl, dry pyridine, rt; d) RCOCl, dry 1,4-dioxane, rt; e) 1 M TBAF in
THF, toluene, reﬂux; f) cat. NaOMe in dry MeOH, rt.



































































































































CAR6993_proof ■ 7 May 2015 ■ 3/9by X-ray crystallography for some iminosugar type GP inhibitors.33
Glycals can also be considered as oxocarbenium ion analogs due to
the resemblance of the shape of these molecules (half-chair
conformation) to that of the glycosyl cation, as it was demonstrated
earlier for glycosidase inhibitors.35 Based on these considerations
we set out to prepare 1-C-hetaryl-glucal derivatives to study their
inhibitory potential against GP. Although D-glucal itself is a weak
inhibitor of RMGPb (Ki¼80 mM),21 it can be assumed that attaching
a heterocycle to the C-1 carbon atom of the glucal may result in
favorable interactions with the protein. In this paper we disclose
our ﬁrst steps towards this type of inhibitors and report the syn-
theses and enzymatic evaluation of each possible isomer of oxa-
diazoles appended to D-glucal by a CeC bond.
2. Results and discussion
2.1. Syntheses
For the preparation of the target compounds two main routes
can be envisaged: a suitably functionalized glucal can be made ﬁrst
followed by the formation of the heterocycle in the ﬁnal stage or,
alternatively, the 1,2-double bond can be introduced into a pre-
formed C-glucopyranosyl heterocycle. The rather scarce literature
of 1-C-hetaryl pyranoid glycals45e48 offers possibilities for both
strategies and neither of them seems superior.47 Since the 2,3,4,6-
tetra-O-benzoyl-b-D-glucopyranosyl cyanide49 23 was shown to
be a common precursor toward each isomer of C-glucopyranosyl-
oxadiazoles40,39,43,50 synthesis and transformations of its unsatu-
rated counterpart 25 (Scheme 1) were studied ﬁrst.
Based on literature analogies46,47,51,52 DBU induced benzoic acid
elimination from 23 as well as Zn/N-methylimidazole mediated
reductive elimination35,53 of the 2,3,4,6-tetra-O-benzoyl-1-bromo-
b-D-glucopyranosyl cyanide49 (24) were probed to get the 1-cyano-
glucal 25 (Scheme 1). The latter method proved to be more efﬁcient
both in terms of purity of the product and overall yields (compare
yields under conditions a and b in Scheme 1 taking into account
that 24 can be obtained almost quantitatively49). By adaptation of a
literature method43 25 was then transformed into amidoxime 26,
which was acylated by acid chlorides to give compounds 27 and 28
in high yields. Subsequent TBAF promoted ring closure54 gave
oxadiazoles 29 and 30, which were debenzoylated by the Zemplen
protocol to furnish 5-aryl-3-(20-deoxy-D-arabino-hex-10-enopyr-
anosyl)-1,2,4-oxadiazoles 31 and 32, respectively, in good yields.Please cite this article in press as: Bokor E, et al., C-(2-Deoxy-D-arabino-
their evaluation as glycogen phosphorylase inhibitors, Carbohydrate ReseFor the preparation of the constitutionally reversed O-perben-
zoylated 3-aryl-5-(20-deoxy-D-arabino-hex-10-enopyranosyl)-1,2,4-
oxadiazoles (35 and 36) both main strategies were investigated
(Scheme 2). 1,3-Dipolar cycloaddition of in situ generated nitrile
oxides39,50 to the O-perbenzoylated 1-cyano-glucal 25 took place
chemoselectively to give unsaturated oxadiazoles 35 and 36.
Additionally, DBU induced b-elimination of PhCOOH from the
appropriate O-perbenzoylated 3-aryl-5-b-D-glucopyranosyl-1,2,4-
oxadiazoles39,50 33 and 34 was also performed. A comparison of
the yields for 35 and 36 from 25 on route a and from 33 and 34 on
route b, respectively, showed the latter method to be superior.
Deprotection of 35 and 36 was carried out by the Zemplen method
to yield 37 and 38, which proved identical with C-glucosyl-1,2,4-
oxadiazoles isolated as by-products in the base-catalyzed trans-
esteriﬁcation of compounds 33 and 34, respectively.39
For the formation of 2-(20-deoxy-D-arabino-hex-10-enopyr-
anosyl)-5-substituted-1,3,4-oxadiazoles (48e50) the easily avail-
able O-perbenzoylated 2-(b-D-glucopyranosyl)-5-substituted-
1,3,4-oxadiazoles40,39 (39e41) were used as starting materials
(Scheme 3). Contrary to the elimination of PhCOOH from 3-aryl-
1,2,4-oxadiazole derivatives (33 and 34 in Scheme 2, route b)
introduction of the double bond into the sugar moiety of 39e41 by
using DBU failed (no or low conversions were observed at either rt.
or reﬂux temperature in CH2Cl2, CHCl3 and toluene). We speculate
that this might be due to different acidity of the C-1-H bonds,
however, no further investigations were devoted to verify this
point. Thereafter, the bromination-reductive elimination sequence
was followed to obtain the unsaturated derivatives 45e47. Bromi-
nation of 40 and 41 was smoothly accomplished to give 43 and 44,
respectively, by using Br2 under irradiation by a heat lamp.55 Taking
into account the susceptibility of the methyl group to be bromi-
nated under the above radical bromination conditions56 trans-
formation of 39 into 42was achieved by using the KBrO3eNa2S2O4/
CH2Cl2eH2O reagent-solvent system57 where the methyl group
remained intact. The brominated compounds 42e44 were then
subjected to reductive elimination by Zn/N-methylimidazole to
obtain 45e47, respectively, in good yields. Removal of the benzoyl
protecting groups by the Zemplen method furnished the ﬁnal
products 48e50 in high yields.
Structural elucidation of the new compounds was based on
proton and carbon NMR data. The 1H NMR spectra for the O-per-
benzoylated oxadiazoles 29, 30, 35, 36, 45e47 displayed narrow
doublets in the range of 6.2e6.6 ppm for the oleﬁnic H-20 protonshex-1-enopyranosyl)-oxadiazoles: synthesis of possible isomers and
arch (2015), http://dx.doi.org/10.1016/j.carres.2015.04.016
Scheme 2. Reagents and conditions: a) RC(Cl)NOH, dry toluene, Ar, reﬂux; b) DBU, dry CH2Cl2, rt; c) cat. NaOMe in dry MeOH, rt.





































































































CAR6993_proof ■ 7 May 2015 ■ 4/9while the same signals appeared in the 5.8e6-1 ppm range for the
deprotected derivatives 31, 32, 37, 38, 48e50. Characteristic 13C
resonances are collected in Table 1 to show the C-10 and C-20 signals
for the double bond in the sugar rings as well as the C-2 or C-3 and
C-5 peaks for the heterocycles.
2.2. Enzyme kinetic studies
The unprotected oxadiazoles 31, 32, 37, 38, and 48e50 were
assayed against rabbit muscle glycogen phosphorylase b as
described earlier58 with maximal inhibitor concentrations of
625 mM. Under these circumstances none of the compounds
inhibited the enzyme (Table 2, entry 2). A comparison with the
‘parent’ C-glucopyranosyl oxadiazoles (Table 2, entry 1) shows that
either the removal of the 2-OH or the change in the conformation of
the sugar ring or both resulted in a complete loss of the activity. The
alterations of the sugar ring could not be compensated by the
additional interactions of the aglycons in the b-channel of the
enzyme, and among others this might be due to a move in their
position as a consequence of the conformational change of theScheme 3. Reagents and conditions: a) KBrO3, Na2S2O4, CH2Cl2, H2O, rt; b) Br2, dry
CHCl3, K2CO3, hn, reﬂux; c) Zn, N-methylimidazole, dry EtOAc, reﬂux; d) cat. NaOMe in
dry MeOH, rt.
Please cite this article in press as: Bokor E, et al., C-(2-Deoxy-D-arabino-
their evaluation as glycogen phosphorylase inhibitors, Carbohydrate Respyranoid ring. Nevertheless, the effect of glucals attached to better
aglycons (e.g., 1,2,4-triazoles 19 in Chart 1) remains an open
question, and further studies in this direction are in progress in our
laboratory.
In conclusion, syntheses of D-glucals conjugated to each isomer
of oxadiazoles by a CeC bond were carried out. These compounds
could be prepared by introducing the double bond in the precursor
glucopyranosyl cyanide followed by further manipulations to
cyclize the aglycon or formation of the unsaturated sugar ring in the
C-glucosyl heterocycle. Either base induced elimination of benzoic
acid from the O-perbenzoylated starting compounds or Zn/N-
methylimidazole mediated reductive elimination from the 1-
bromoglucosyl precursor molecules could be applied for the for-
mation of the hex-1-enopyranosyl rings. However, no general
sequence of the above steps could be established, therefore, speciﬁc
syntheses had to be elaborated for each target compound. None of
the studied glucal derived oxadiazoles showed inhibition against
RMGPb indicating that the binding of the these aglycons was not
strong enough to override the detrimental effects of the changes in































Melting points were measured on a Koﬂer hot-stage and are
uncorrected. Optical rotations were determined with a Per-
kineElmer 241 polarimeter at rt. NMR spectra were recorded with
Bruker 360 (360/90 MHz for 1H/13C) or Bruker 400 (400/100 MHz
for 1H/13C) spectrometers. Chemical shifts are referenced to Me4Si
(1H), or to the residual solvent signals (13C). Mass spectra were
obtained by a Thermo Scientific LTQ XL instrument (sample injec-
tion in 50:50:0.1 CH3CNeH2OeHCOOH or 50:50:0.1
MeOHeH2OeCH3COONH4). TLC was performed on DC-Alurolle
Kieselgel 60 F254 (Merck) plates, visualized under UV light and by
gentle heating. For column chromatography Kieselgel 60 (Merck,
particle size 0.063e0.200 mm) was used. Toluene, CH2Cl2, CHCl3,
EtOAc were distilled from P4O10 and stored over 4 Å molecular
sieves or sodium wires. MeOH was puriﬁed by distillation after
reﬂuxing for a couple of hours with magnesium turnings and
iodine. 1,4-Dioxane was distilled from sodium benzophenone ketyl
and stored over sodium wires. 2,3,4,6-Tetra-O-benzoyl-b-D-gluco-
pyranosyl cyanide49 (23), 2,3,4,6-tetra-O-benzoyl-1-bromo-1-
deoxy-b-D-glucopyranosyl cyanide49 (24), N-hydroxy-arene-
carboximidoyl chlorides,39 3-aryl-5-(20,30,40,60-tetra-O-benzoyl-b-
D-glucopyranosyl)-1,2,4-oxadiazoles39 (33 and 34) and 2-
(20,30,40,60-tetra-O-benzoyl-b-D-glucopyranosyl)-5-substituted-
1,2,4-oxadiazoles40,39 (39e41) were synthesized according to
published procedures.hex-1-enopyranosyl)-oxadiazoles: synthesis of possible isomers and
earch (2015), http://dx.doi.org/10.1016/j.carres.2015.04.016
Table 1
Characteristic 13C resonances of the oxadiazole derivatives
C-10 C-20 C-3 C-5 C-10 C-20 C-3 C-5
R¼Ph 29 144.5 103.2 164.9 175.9 31 141.3 110.4 164.8 174.6
R¼2-naphthyl 30 144.5 103.2 164.9 175.9 32 141.3 110.5 164.9 174.8
R¼Ph 35 141.7 105.2 168.8 170.3 37 141.1 112.9 169.8 172.9
R¼2-naphthyl 36 141.7 105.3 168.9 170.4 38 138.7 113.0 168.0 171.3
C-2 C-2
R¼Me 45 141.3 102.4 160e166a 48 140.2 110.2 166.1b 162.0b
R¼Ph 46 141.2 102.6 159e166a 49 138.2 110.1 163.7b 159.9b
R¼2-naphthyl 47 141.3 102.7 159e166a 50 138.3 110.2 163.9b 160.0b
a The range of the C-2, C-5 and CO signals without assignment.
b Interchangable assignments.

















































































































CAR6993_proof ■ 7 May 2015 ■ 5/93.2. General procedure I for the preparation of 3,4,6-tri-O-benzoyl-
2-deoxy-D-arabino-hex-1-enopyranosyl derivatives (25, 35, 36) by
DBU induced PhCOOH elimination
To a solution of the corresponding 2,3,4,6-tetra-O-benzoyl-b-D-
glucopyranosyl derivative (23, 33, 34) in anhydrous CH2Cl2
(1 mmol/10 mL) DBU (1.5e2.0 equiv) was added and the reaction
mixture was stirred at rt. When the TLC (1:4 EtOAc-hexane)
showed total consumption of the starting material the mixture
was diluted with CH2Cl2, extracted with satd aq KHSO4 solution
then with water. The organic phase was dried over MgSO4, ﬁltered
and concentrated under diminished pressure. The residue was
puriﬁed by column chromatography.
3.3. General procedure II for the synthesis of 3,4,6-tri-O-benzoyl-2-
deoxy-D-arabino-hex-1-enopyranosyl derivatives (25, 45, 47) by Zn/
N-methylimidazole mediated reductive elimination
The corresponding 2,3,4,6-tetra-O-benzoyl-1-bromo-1-deoxy-
b-D-glucopyranosyl derivative (24, 42e44) was dissolved in anhy-
drous EtOAc (1 mmol/10 mL), activated zinc dust35 (10 equiv) wasTable 2
Inhibition (Ki [mM]) of RMGPb by C-glycosyl oxadiazoles
Entry Sugar part Heterocycle
R¼Ph R¼2-naphthyl R¼Ph
1 14
10% inh. at 625 mM43 3843 6439
2 31 32 37
No inhibition at 625 mM concentration.
Please cite this article in press as: Bokor E, et al., C-(2-Deoxy-D-arabino-
their evaluation as glycogen phosphorylase inhibitors, Carbohydrate Reseadded and the mixture was stirred at reﬂux temperature. N-
Methylimidazole (5 equiv) was added to the boiling suspension,
and the heating was continued until the starting material dis-
appeared (TLC, 3:7 EtOAc-hexane). Charcoal was added to the hot
mixture and the solids were ﬁltered off through a pad of Celite. The
ﬁltrate was then extracted with 1 M aq HCl solution, satd aq
NaHCO3 solution and water. The organic phase was dried over
MgSO4, ﬁltered and evaporated. The residue was puriﬁed by col-
umn chromatography.
3.4. General procedure III for the synthesis of O-aroyl-C-(3,4,6-tri-
O-benzoyl-2-deoxy-D-arabino-hex-1-enopyranosyl)
formamidoximes (27 and 28)
To the solution of C-(3,4,6-tri-O-benzoyl-2-deoxy-D-arabino-
hex-1-enopyrano-syl)formamidoxime (26) in anhydrous 1,4-
dioxane (1 mmol/5 mL) an acid chloride (1.1 equiv) was added
and the reaction mixture was stirred at rt. After total consumption
of the starting material (TLC 1:2 EtOAc-hexane) the solvent was
removed under reduced pressure. The crude product was then
puriﬁed by column chromatography.R¼2-naphthyl R¼Me R¼Ph R¼2-naphthyl
15 16 17
12 (2.4)39 21240 14541 10% inh. at 625 mM39 10% inh. at 625 mM39
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CAR6993_proof ■ 7 May 2015 ■ 6/93.5. General procedure IV for the synthesis of 5-aryl-3-(30,40,60-tri-
O-benzoyl-20-deoxy-D-arabino-hex-10-enopyranosyl)-1,2,4-
oxadiazoles (29 and 30)
An O-aroyl-C-(3,4,6-tri-O-benzoyl-2-deoxy-D-arabino-hex-1-
enopyranosyl)formamidoxime (27 or 28) was dissolved in toluene
(1 mmol/15 mL), a 1 M solution of Bu4NF in THF (0.1 equiv) was
added and the mixture was reﬂuxed. After completion of the re-
action monitored by TLC (1:2 EtOAc-hexane) the solvent was
removed and the residue was puriﬁed by column chromatography.
3.6. General procedure V for removal of benzoyl protecting groups
by the Zemplen protocol
To a solution of an O-perbenzoylated compound in anhydrous
MeOH (5 mL/100 mg, a few drops of anhydrous CHCl3 were added
in case of incomplete dissolution) a catalytic amount of a NaOMe
solution (1 M in MeOH) was added and the mixture was left at rt.
After completion of the reaction monitored by TLC (9:1
CHCl3eMeOH) the mixture was neutralized with a cation exchange
resin Amberlyst 15 (Hþ form), then the resinwas ﬁltered off and the
solvent was removed. The crude product was puriﬁed by column
chromatography.
3.7. General procedure VI for the synthesis of 3-aryl-5-(30,40,60-tri-
O-benzoyl-20-deoxy-D-arabino-hex-10-enopyranosyl)-1,2,4-
oxadiazole (35 and 36) from cyanide 25 by 1,3-dipolar
cycloaddition
3,4,6-Tri-O-benzoyl-2-deoxy-D-arabino-hex-1-enopyranosyl
cyanide (25, 0.50 g, 1.03 mmol) and the corresponding N-hydroxy-
arenecarboximidoyl chloride (5.0 equiv) were dissolved in anhy-
drous toluene (12 mL) and stirred at reﬂux temperature under Ar
atmosphere. To this mixture a solution of Et3N (1.08 mL, 7.76 mmol,
7.5 equiv) in anhydrous toluene (12 mL) was added with a syringe
pump in 8 h. The reactionmixturewas heated for an additional 12 h
and then the solvent was removed under reduced pressure. The
residue was puriﬁed by column chromatography.
3.8. General procedure VII for the preparation of 5-aryl-2-
(20,30,40,60-tetra-O-benzoyl-10-bromo-10-deoxy-b-D-
glucopyranosyl)-1,3,4-oxadiazoles (43 and 44)
A 5-aryl-2-(20,30,40,60-tetra-O-benzoyl-b-D-glucopyranosyl)-
1,3,4-oxadiazole (40 or 41, 2.0 g) was dissolved in anhydrous CHCl3
(30 mL) in an Erlenmeyer ﬂask, and bromine (3 equiv) and some
solid K2CO3 were added. The mixture was placed above a heat lamp
(375 W, distance from the lamp 2e3 cm, height of the solution
1e2 cm), and reﬂuxed. After total consumption of the starting
material monitored by TLC (1:3 EtOAc-hexane) the mixture was
diluted with CHCl3 (100 mL) and extracted with 1 M aq Na2SO3
solution (80 mL), satd aq NaHCO3 solution (280 mL) and with
water (80 mL). The organic phase was dried over MgSO4, ﬁltered
and evaporated under diminished pressure. The residual crude
product was purified either by crystallization or by column
chromatography.
3.9. Synthesis and characterization of the compounds
3.9.1. 3,4,6-Tri-O-benzoyl-2-deoxy-D-arabino-hex-1-enopyranosyl
cyanide (25)
A: Prepared from cyanide 2349 (10.00 g, 16.50 mmol) and DBU
(4.92 mL, 33.00 mmol) according to General procedure I (Section
3.2). Reaction time: 3 h. Puriﬁed by column chromatography (1:4
EtOAc-hexane) to yield 3.97 g (50%) colorless syrup.Please cite this article in press as: Bokor E, et al., C-(2-Deoxy-D-arabino-
their evaluation as glycogen phosphorylase inhibitors, Carbohydrate ResB: Prepared from cyanide 2449 (4.13 g, 6.04 mmol) according to
General procedure II (Section 3.3). Reaction time: 2 h. Puriﬁed by
column chromatography (1:4 EtOAc-hexane) to yield 2.08 g (92%)
colorless syrup. Rf: 0.39 (1:4 EtOAc-hexane); [a]D 43 (c 0.50,
CHCl3); 1H NMR (CDCl3) d (ppm): 8.05e7.97 (6H, m, aromatics),
7.60e7.54 (3H, m, aromatics), 7.46e7.39 (9H, m, aromatics), 5.99
(1H, d, J¼4.0 Hz, H-2), 5.81 (1H, pseudo t, J¼5.9, 5.3 Hz, H-4), 5.76
(1H, pseudo t, J¼5.3, 4.0 Hz, H-3), 4.85 (1H, ddd, J¼5.9, 5.3, < 1 Hz,
H-5), 4.75e4.66 (2H, m, H-6a, H-6b); 13C NMR (CDCl3) d (ppm):
165.9, 165.2, 164.7 (C]O), 133.8, 133.7, 133.3 (aromatics), 131.0 (C-
1), 129.8e128.4 (aromatics), 112.9 (C^N), 112.1 (C-2), 75.8, 66.3,
66.0 (C-3eC-5), 61.0 (C-6). MS-ESI (m/z, positive mode): Calcd for




cyanide (25, 3.00 g, 6.21 mmol) and hydroxylamine hydrochloride
(1.08 g, 15.53 mmol, 2.5 equiv) were stirred in anhydrous pyridine
(20 mL) at rt. When the TLC (1:1 EtOAc-hexane) showed total
disappearance of the starting material (2 d) the reaction mixture
was diluted with EtOAc (200 mL) and extracted with water
(200 mL). The organic phase was then washed with 1 M aq HCl
solution (200mL), with satd aq NaHCO3 solution (200mL) andwith
water (200 mL), respectively. The separated organic phase was
dried over MgSO4, ﬁltered and the solvent was removed by
diminished pressure. The resulted colorless oil (2.70 g, 84%) was
then usedwithout further puriﬁcation. Rf: 0.47 (1:1 EtOAc-hexane);
[a]D 23 (c 0.50, CHCl3); 1H NMR (CDCl3) d (ppm): 8.04e7.97 (6H,
m, aromatics), 7.56e7.48 (3H, m, aromatics), 7.43e7.35 (6H, m, ar-
omatics), 5.83e5.78 (3H, m, H-2, H-3, H-4), 4.91 (2H, s, NH2),
4.80e4.69 (3H, m, H-5, H-6a, H-6b); 13C NMR (CDCl3) d (ppm):
166.1, 165.6, 165.0 (C]O), 147.6, 146.3 (C-1, C]N), 133.5e128.4
(aromatics), 97.0 (C-2), 74.7, 67.5 (2) (C-3eC-5), 61.6 (C-6). MS-ESI




Prepared from amidoxime 26 (1.50 g, 2.90 mmol) and benzoyl
chloride (0.37 mL, 3.19 mmol) according to General procedure III
(Section 3.4). Reaction time: 1 d. Puriﬁed by column chromatog-
raphy (1:3 EtOAc-hexane) to yield 1.53 g (85%) white amorphous
solid. Rf: 0.53 (1:1 EtOAc-hexane); [a]D13 (c 0.50, CHCl3); 1H NMR
(CDCl3) d (ppm): 8.04e7.37 (20H, m, aromatics), 6.22 (1H, d,
J¼3.9 Hz, H-2), 5.86 (1H, pseudo t, J¼4.7, 3.9 Hz, H-3), 5.80 (1H,
pseudo t, J¼5.5, 4.7 Hz, H-4), 5.43 (2H, s, NH2), 4.86e4.69 (3H, m, H-
5, H-6a, H-6b); 13C NMR (CDCl3) d (ppm): 166.3, 165.4, 165.1, 163.7
(C]O), 152.1, 144.7 (C]N, C-1), 133.7e128.6 (aromatics), 100.1 (C-
2), 75.5, 67.5, 66.9 (C-3eC-5), 61.6 (C-6). MS-ESI (m/z, positive
mode): Calcd for C35H29N2O9þ [MþH]þ: 621.2. Found: 621.3.
3.9.4. O-(2-Naphthoyl)-C-(3,4,6-tri-O-benzoyl-2-deoxy-D-arabino-
hex-1-enopyranosyl)-formamidoxime (28)
Prepared from amidoxime 26 (2.00 g, 3.87 mmol) and 2-
naphthoyl chloride (0.81 g, 4.26 mmol) according to General pro-
cedure III (Section 3.4). Reaction time: 1 d. Puriﬁed by column
chromatography (1:3 EtOAc-hexane) to yield 2.21 g (85%) white
amorphous solid. Rf: 0.33 (1:3 EtOAc-hexane); [a]D 10 (c 0.50,
CHCl3); 1H NMR (CDCl3) d (ppm): 8.58 (1H, s, aromatic), 8.04e7.34
(21H, m, aromatics), 6.27 (1H, d, J¼4.0 Hz, H-2), 5.88 (1H, pseudo t,
J¼5.3, 4.0 Hz, H-3), 5.84 (1H, pseudo t, J¼5.9, 5.3 Hz, H-4), 5.57 (2H,
s, NH2), 4.86e4.70 (3H, m, H-5, H-6a, H-6b); 13C NMR (CDCl3)
d (ppm): 166.3, 165.4, 165.1, 163.9 (C]O), 152.2, 144.7 (C]N, C-1),
135.4e124.9 (aromatics), 100.1 (C-2), 75.4, 67.5, 67.0 (C-3eC-5), 61.6hex-1-enopyranosyl)-oxadiazoles: synthesis of possible isomers and
earch (2015), http://dx.doi.org/10.1016/j.carres.2015.04.016







































































































































Prepared from compound 27 (1.00 g, 1.61 mmol) according to
General procedure IV (Section 3.5). Reaction time: 1 d. Puriﬁed by
column chromatography (1:2 EtOAc-hexane) to yield 0.96 g (99%)
white solid. Mp: 154e155 C; [a]D þ24 (c 0.50, CHCl3); 1H NMR
(CDCl3) d (ppm): 8.16e7.39 (20H, m, aromatics), 6.46 (1H, d,
J¼3.9 Hz, H-20), 5.96e5.94 (2H, m, H-30, H-40), 5.05 (1H, ddd, J¼6.3,
5.5, 4.7 Hz, H-50), 4.87 (1H, dd, J¼12.5, 6.3 Hz, H-60a), 4.80 (1H, dd,
J¼12.5, 4.7 Hz, H-60b); 13C NMR (CDCl3) d (ppm): 175.9 (oxadiazole
C-5), 166.2, 165.7, 165.2, 164.9 (C]O, oxadiazole C-3), 144.5 (C-10),
133.6e123.8 (aromatics), 103.2 (C-20), 75.0, 67.4, 67.0 (C-30eC-50),
61.7 (C-60). MS-ESI (m/z, positive mode): Calcd for C35H27N2O8þ
[MþH]þ: 603.2. Found: 603.3.
3.9.6. 5-(2-Naphthyl)-3-(30,40,60-tri-O-benzoyl-20-deoxy-D-
arabino-hex-10-enopyranosyl)-1,2,4-oxadiazole (30)
Prepared from compound 28 (1.00 g, 1.49 mmol) according to
General procedure IV (Section 3.5). Reaction time: 1 d. Puriﬁed by
column chromatography (1:2 EtOAc-hexane) to yield 0.86 g (88%)
white amorphous solid. Rf: 0.42 (1:2 EtOAc-hexane); [a]D þ20 (c
0.50, CHCl3); 1H NMR (CDCl3) d (ppm): 8.68 (1H, s, aromatic),
8.14e7.38 (21H, m, aromatics), 6.53 (1H, d, J¼3.3 Hz, H-20),
6.00e5.97 (2H, m, H-30, H-40), 5.07 (1H, ddd, J¼5.9, 5.3, 4.6 Hz, H-
50), 4.91 (1H, dd, J¼11.9, 5.9 Hz, H-60a), 4.83 (1H, dd, J¼11.9, 4.6 Hz,
H-60b); 13C NMR (CDCl3) d (ppm): 175.9 (oxadiazole C-5), 166.2,
165.7, 165.1, 164.9 (C]O, oxadiazole C-3), 144.5 (C-10), 135.3e120.9
(aromatics), 103.2 (C-20), 74.9, 67.4, 67.0, (C-30eC-50), 61.7 (C-60).




Prepared from compound 29 (0.30 g, 0.50 mmol) according to
General procedure V (Section 3.6). Reaction time: 1 h. Puriﬁed by
column chromatography (9:1 CHCl3eMeOH) to yield 0.10 g (72%)
white solid. Mp: 212e214 C; [a]D þ16 (c 0.50, DMSO); 1H NMR
(DMSO-d6) d (ppm): 8.12 (2H, d, J¼7.3 Hz, aromatics), 7.72 (1H, t,
J¼7.3 Hz, aromatic), 7.64 (2H, t, J¼7.3 Hz, aromatics), 5.88 (1H, d,
J¼2.0 Hz, H-20), 5.36, 5.30, 4.76 (31H, 3OH), 4.19e4.15,
3.92e3.89, 3.85e3.81, 3.77e3.71, 3.62e3.56 (51H, 5m, H-30, H-40,
H-50, H-60a, H-60b); 13C NMR (DMSO-d6) d (ppm): 174.6 (oxadiazole
C-5), 164.8 (oxadiazole C-3), 141.3 (C-10), 133.4, 129.6 (2), 127.9 (2),
123.2 (aromatics), 110.4 (C-20), 80.8, 68.4, 68.1 (C-30eC-50), 59.9 (C-




Prepared from compound 30 (0.30 g, 0.50 mmol) according to
General procedure V (Section 3.6). Reaction time: 1 h. Puriﬁed by
column chromatography (9:1 CHCl3eMeOH) to yield 0.13 g (85%)
white solid. Mp: 199e200 C; [a]D þ20 (c 0.50, DMSO); 1H NMR
(DMSO-d6) d (ppm): 8.81 (1H, s, aromatic), 8.21e7.64 (6H, m, aro-
matics), 5.93 (1H, s, H-20), 5.05 (3H, br signal, OH), 4.20e4.19, 3.91,
3.86e3.83, 3.78e3.74, 3.64e3.59 (51H, 5m, H-30, H-40, H-50, H-60a,
H-60b); 13C NMR (DMSO-d6) d (ppm): 174.8 (oxadiazole C-5), 164.9
(oxadiazole C-3), 141.3 (C-10), 134.8, 132.3, 129.4, 129.3, 129.1, 128.9,
127.9, 127.5, 123.5, 120.4 (aromatics), 110.5 (C-20), 80.8, 68.4, 68.3
(C-30eC-50), 60.0 (C-60). MS-ESI (m/z, negative mode): Calcd for
C20H19N2O7‒ [MþAcO]‒: 399.1. Found: 399.3.Please cite this article in press as: Bokor E, et al., C-(2-Deoxy-D-arabino-
their evaluation as glycogen phosphorylase inhibitors, Carbohydrate Rese3.9.9. 3-Phenyl-5-(30,40,60-tri-O-benzoyl-20-deoxy-D-arabino-hex-
10-enopyranosyl)-1,2,4-oxadiazole (35)
A: Prepared from oxadiazole 3339 (0.20 g, 0.28 mmol) and DBU
(62 mL, 0.41 mmol) according to General procedure I (Section 3.2).
Reaction time: 1 d. Puriﬁed by column chromatography (1:7 EtOAc-
hexane) to yield 0.13 g (78%) pale yellow syrup.
B: Prepared from cyanide 25 (0.50 g,1.03mmol) and N-hydroxy-
benzenecarboximidoyl chloride39 (0.80 g, 5.17 mmol) according to
General procedure VI (Section 3.7). Puriﬁed by column chroma-
tography (1:8 EtOAc-hexane) to yield 0.37 g (60%) pale yellow
syrup. Rf: 0.67 (1:2 EtOAc-hexane); [a]D11 (c 0.50, CHCl3). 1H NMR
(CDCl3) d (ppm): 8.12e8.02 (8H, m, aromatics), 7.63e7.41 (12H, m,
aromatics), 6.55 (1H, d, J¼4.7 Hz, H-20), 5.92e5.91 (2H, m, H-30, H-
40), 5.07 (1H, ddd, J¼7.0, 6.3, 4.7 Hz, H-50), 4.89 (1H, dd, J¼11.7,
6.3 Hz, H-60a), 4.78 (1H, dd, J¼11.7, 4.7 Hz, H-60b); 13C NMR (CDCl3)
d (ppm): 170.3, 168.8 (oxadiazole C-3, C-5), 166.0, 165.4, 164.9 (C]
O), 141.7 (C-10), 133.7e126.2 (aromatics), 105.2 (C-20), 75.2, 67.0,
66.3 (C-30eC-50), 61.2 (C-60). MS-ESI (m/z, positive mode): Calcd for
C35H27N2O8þ [MþH]þ: 603.2. Found: 603.8.
3.9.10. 3-(2-Naphthyl)-5-(30,40,60-tri-O-benzoyl-20-deoxy-D-
arabino-hex-10-enopyrano-syl)-1,2,4-oxadiazole (36)
A: Prepared from oxadiazole 3439 (0.5 g, 0.65 mmol) and DBU
(145 mL, 0.97 mmol) according to General procedure I (Section 3.2).
Reaction time: 2 h. Puriﬁed by column chromatography (1:4 EtOAc-
hexane) to yield 0.30 g (70%) white solid.
B: Prepared from cyanide 25 (0.5 g, 1.03 mmol) and N-hydroxy-
naphthalene-2-carboximidoyl chloride39 (1.06 g, 5.17 mmol) ac-
cording to General procedure VI (Section 3.7). Puriﬁed by column
chromatography (toluene) to yield 0.34 g (50%) white solid. Mp:
184e185 C; [a]D 6 (c 0.50, CHCl3). 1H NMR (CDCl3) d (ppm): 8.66
(1H, s, aromatic), 8.24e7.41 (21H, m, aromatics), 6.60 (1H, d,
J¼4.7 Hz, H-20), 5.94e5.93 (2H, m, H-30, H-40), 5.10 (1H, ddd, J¼6.3,
4.7, 3.9 Hz, H-50), 4.92 (1H, dd, J¼12.5, 6.3 Hz, H-60a), 4.80 (1H, dd,
J¼12.5, 4.7 Hz, H-60b); 13C NMR (CDCl3) d (ppm): 170.4, 168.9
(oxadiazole C-3, C-5), 166.0, 165.4, 164.9 (C]O), 141.7 (C-10),
134.6e123.4 (aromatics), 105.3 (C-20), 75.2, 67.0, 66.2 (C-30eC-50),
61.2 (C-60). MS-ESI (m/z, positive mode): Calcd for C39H29N2O8þ
[MþH]þ: 653.2. Found: 653.1.
3.9.11. 5-(20-Deoxy-D-arabino-hex-10-enopyranosyl)-3-phenyl-
1,2,4-oxadiazole39 (37)
Prepared from compound 35 (0.20 g, 0.33 mmol) according to
General procedure V (Section 3.6). Reaction time: 8 h. Puriﬁed by
column chromatography (9:1 CHCl3eMeOH) to yield 85 mg (89%)
white solid. Mp: 198e199 C; [a]D 8 (c 0.45, DMSO); 1H NMR
(CD3OD) d (ppm): 8.06 (2H, d, J¼7.8 Hz, aromatic), 7.58e7.51 (3H, m,
aromatics), 6.13 (1H, d, J¼2.3 Hz, H-20), 4.35 (1H, dd, J¼7.0, 2.3 Hz,
H-30), 4.08 (1H, ddd, J¼7.8, 5.5, 2.3 Hz, H-50), 4.03 (1H, dd, J¼12.5,
2.3 Hz, H-60a), 3.94 (1H, dd, J¼12.5, 5.5 Hz, H-60b), 3.76 (1H, dd,
J¼7.8, 7.0 Hz, H-40); 13C NMR (CD3OD) d (ppm): 172.9, 169.8 (oxa-
diazole C-3, C-5), 141.1 (C-10), 132.7e127.7 (aromatics), 112.9 (C-20),
82.3, 70.3, 69.7 (C-30eC-50), 61.9 (C-60).
3.9.12. 5-(20-Deoxy-D-arabino-hex-10-enopyranosyl)-3-(2-
naphthyl)-1,2,4-oxadiazole39 (38)
Prepared from compound 36 (0.19 g, 0.29 mmol) according to
General procedure V (Section 3.6). Reaction time: 4 h. Puriﬁed by
column chromatography (9:1 CHCl3eMeOH) to yield 95 mg (96%)
white solid. Mp: 202e203 C; [a]D 8 (c 0.50, DMSO); 1H NMR
(DMSO-d6þ1e2 drops of D2O) d (ppm): 8.55 (1H, s, aromatic),
8.06e7.95 (4H, m, aromatics), 7.63e7.56 (2H, m, aromatics), 6.05
(1H, d, J¼3.1 Hz, H-20), 4.19 (1H, dd, J¼6.3, 3.1 Hz, H-30), 3.98 (1H,
ddd, J¼8.6, 5.5, 2.3 Hz, H-50), 3.83 (1H, dd, J¼12.5, 2.3 Hz, H-60a),
3.74 (1H, dd, J¼12.5, 5.5 Hz, H-60b), 3.59 (1H, dd, J¼8.6, 6.3 Hz, H-hex-1-enopyranosyl)-oxadiazoles: synthesis of possible isomers and
arch (2015), http://dx.doi.org/10.1016/j.carres.2015.04.016



































































































































CAR6993_proof ■ 7 May 2015 ■ 8/940); 13C NMR (DMSO-d6) d (ppm): 171.3, 168.0 (oxadiazole C-3, C-5),
138.7 (C-10), 134.2e123.2 (aromatics), 113.0 (C-20), 81.1, 67.9, 67.7
(C-30eC-50), 59.6 (C-60). MS-ESI (m/z, negative mode): Calcd for




1,3,4-oxadiazole40 (39, 0.85 g, 1.28 mmol) was dissolved in CH2Cl2
(25 mL), and an aqueous solution of KBrO3 (1.29 g, 7.70 mmol,
6 equiv in 25 mL water) was added. To the stirred heterogenous
mixture an aqueous solution of Na2S2O4 (1.34 g, 7.70 mmol, 6 equiv
in 25 mL water) was added dropwise over 10 min. The mixture was
then stirred at rt and the reaction was monitored by TLC (1:1
EtOAc-hexane). After disappearance of the starting material (1 d)
the reaction mixture was diluted with CH2Cl2 (50 mL), extracted
with 1 M aq solution of Na2SO3 (30 mL), with satd aq NaHCO3
(230 mL) and with water (30 mL), respectively. The organic phase
was dried over MgSO4, ﬁltered and evaporated under diminished
pressure. The residue was purified by column chromatography (1:2
EtOAc-hexane) to yield 0.61 g (64%) white amorphous solid. Rf: 0.49
(1:1 EtOAc-hexane); [a]D þ141 (c 0.50, CHCl3); 1H NMR (CDCl3)
d (ppm): 8.07e7.25 (20H, m, aromatics), 6.30 (1H, pseudo t, J¼9.4,
9.4 Hz, H-30 or H-40), 6.07 (1H, d, J¼9.4 Hz, H-20), 5.95 (1H, pseudo t,
J¼9.4, 9.4 Hz, H-30 or H-40), 4.92 (1H, ddd, J¼9.4, 4.7, 2.3 Hz, H-50),
4.73 (1H, dd, J¼12.5, 2.3 Hz, H-60a), 4.61 (1H, dd, J¼12.5, 4.7 Hz, H-
60b), 2.48 (3H, s, CH3); 13C NMR (CDCl3) d (ppm): 165.8, 165.4, 165.0,
164.8, 164.3, 162.4 (C]O, oxadiazole C-2, C-5), 133.6e128.2 (aro-
matics), 90.8 (C-10), 74.8, 71.9, 71.4, 67.5 (C-20eC-50), 61.7 (C-60), 10.9
(CH3). MS-ESI (m/z, positive mode): Calcd for C37H30BrN2O10þ
[MþH]þ: 741.1. Found: 741.5.
3.9.14. 2-Phenyl-5-(20,30,40,60-tetra-O-benzoyl-10-bromo-10-deoxy-
b-D-glucopyranosyl)-1,3,4-oxadiazole (43)
Prepared from oxadiazole 4039 (2.00 g, 2.76 mmol) according to
General procedure VII (Section 3.8). Reaction time: 2 h. Puriﬁed by
crystallization from EtOH to yield 1.49 g (67%) white solid. Mp:
decomposition above 152 C; [a]D þ137 (c 0.50, CHCl3); 1H NMR
(CDCl3) d (ppm): 8.08, 8.00, 7.96, 7.92, 7.85 (52H, 5d, J¼7.3 Hz in
each, aromatics), 7.60e7.26 (15H, m, aromatics), 6.32 (1H, pseudo t,
J¼9.2, 9.2 Hz, H-30 or H-40), 6.12 (1H, d, J¼9.2 Hz, H-20), 5.96 (1H,
pseudo t, J¼9.9, 9.2 Hz, H-30 or H-40), 4.95 (1H, ddd, J¼9.9, 4.6,
2.6 Hz, H-50), 4.77 (1H, dd, J¼12.6, 2.6 Hz, H-60a), 4.65 (1H, dd,
J¼12.6, 4.6 Hz, H-60b); 13C NMR (CDCl3) d (ppm): 165.9, 165.6, 165.5,
164.9, 164.4, 162.2 (C]O, oxadiazole C-2, C-5), 133.7e127.2 (aro-
matics), 90.9 (C-10), 74.9, 72.0, 71.5, 67.8 (C-20eC-50), 61.8 (C-60).




Prepared from oxadiazole 4139 (2.00 g, 2.58 mmol) according to
General procedure VII (Section 3.8). Reaction time: 2 h. Puriﬁed by
column chromatography (1:3 EtOAc-hexane) to yield 2.09 g (95%)
colorless syrup. Rf: 0.35 (EtOAc-hexane 1:2); [a]D þ104 (c 0.50,
CHCl3); 1H NMR (CDCl3) d (ppm): 8.37 (1H, s, aromatic), 8.10e7.25
(26H, m, aromatics), 6.36 (1H, pseudo t, J¼9.4, 9.4 Hz, H-30 or H-40),
6.15 (1H, d, J¼9.4 Hz, H-20), 6.00 (1H, pseudo t, J¼9.4, 9.4 Hz, H-30 or
H-40), 4.99 (1H, ddd, J¼9.4, 4.7, 2.3 Hz, H-50), 4.80 (1H, dd, J¼12.5,
2.3 Hz, H-60a), 4.69 (1H, dd, J¼12.5, 4.7 Hz, H-60b); 13C NMR (CDCl3)
d (ppm): 165.9, 165.8, 165.5, 164.9, 164.4, 162.3 (C]O, oxadiazole C-
2, C-5), 134.8e120.1 (aromatics), 90.9 (C-10), 74.9, 72.0, 71.5, 67.7 (C-
20eC-50), 61.8 (C-60). MS-ESI (m/z, positive mode): Calcd for
C46H34BrN2O10þ [MþH]þ: 853.1. Found: 853.3.Please cite this article in press as: Bokor E, et al., C-(2-Deoxy-D-arabino-
their evaluation as glycogen phosphorylase inhibitors, Carbohydrate Res3.9.16. 2-Methyl-5-(30,40,60-tri-O-benzoyl-20-deoxy-D-arabino-hex-
10-enopyranosyl)-1,3,4-oxadiazole (45)
Prepared from compound 42 (0.40 g, 0.54 mmol) according to
General procedure II (Section 3.3). Reaction time: 10 min. Puriﬁed
by column chromatography (1:1 EtOAc-hexane) to yield 0.20 g
(69%) colorless syrup. Rf: 0.40 (1:1 EtOAc-hexane); [a]D29 (c 0.50,
CHCl3); 1H NMR (CDCl3) d (ppm): 8.05e7.39 (15H, m, aromatics),
6.24 (1H, d, J¼3.9 Hz, H-20), 5.90 (1H, pseudo t, J¼5.5, 4.7 Hz, H-30 or
H-40) 5.86 (1H, pseudo t, J¼4.7, 3.9 Hz, H-30 or H-40), 5.01 (1H, ddd,
J¼6.3, 5.5, 4.7 Hz, H-50), 4.85 (1H, dd, J¼11.7, 6.3 Hz, H-60a), 4.75 (1H,
dd, J¼11.7, 4.7 Hz, H-60b), 2.57 (3H, s, CH3); 13C NMR (CDCl3)
d (ppm): 166.0,165.5,164.9,164.2,159.9 (C]O, oxadiazole C-2, C-5),
141.3 (C-10), 133.7e128.4 (aromatics), 102.4 (C-20), 75.1, 67.0, 66.5
(C-30eC-50), 61.3 (C-60), 11.0 (CH3). MS-ESI (m/z, positive mode):
Calcd for C30H25N2O8þ [MþH]þ: 541.2. Found: 541.7.
3.9.17. 2-Phenyl-5-(30,40,60-tri-O-benzoyl-20-deoxy-D-arabino-hex-
10-enopyranosyl)-1,3,4-oxadiazole (46)
Prepared from compound 43 (1.00 g, 1.24 mmol) according to
General procedure II (Section 3.3). Reaction time: 15 min. Puriﬁed
by column chromatography (2:3 EtOAc-hexane) to yield 0.68 g
(91%) colorless syrup. Rf: 0.33 (2:3 EtOAc-hexane); [a]D 7 (c 0.50,
CHCl3); 1H NMR (CDCl3) d (ppm): 8.08e7.39 (20H, m, aromatics),
6.38 (1H, d, J¼3.9 Hz, H-20), 5.96e5.92 (2H, m, H-30, H-40), 5.08 (1H,
ddd, J¼6.3, 5.5, 4.7 Hz, H-50), 4.94 (1H, dd, J¼11.7, 6.3 Hz, H-60a),
4.79 (1H, dd, J¼11.7, 4.7 Hz, H-60b); 13C NMR (CDCl3) d (ppm): 165.9,
165.4, 164.8 (2), 159.4 (C]O, oxadiazole C-2, C-5), 141.2 (C-10),
133.6e123.1 (aromatics), 102.6 (C-20), 75.0, 67.0, 66.4 (C-30eC-50),
61.2 (C-60). MS-ESI (m/z, positive mode): Calcd for C35H27N2O8þ
[MþH]þ: 603.2. Found: 603.3.
3.9.18. 2-(2-Naphthyl)-5-(30,40,60-tri-O-benzoyl-20-deoxy-D-
arabino-hex-10-enopyrano-syl)-1,3,4-oxadiazole (47)
Prepared from compound 44 (1.00 g, 1.17 mmol) according to
General procedure II (Section 3.3). Reaction time: 15 min. Puriﬁed
by column chromatography (2:3 EtOAc-hexane) to yield 0.67 g
(87%) colorless syrup. Rf: 0.34 (1:2 EtOAc-hexane); [a]D þ9 (c 0.50,
CHCl3); 1H NMR (CDCl3) d (ppm): 8.53 (1H, s, aromatic), 8.13e7.40
(21H, m, aromatics), 6.43 (1H, d, J¼3.9 Hz, H-20), 5.98e5.93 (2H, m,
H-30, H-40), 5.10 (1H, ddd, J¼6.3, 5.5, 4.7 Hz, H-50), 4.96 (1H, dd,
J¼11.7, 6.3 Hz, H-60a), 4.81 (1H, dd, J¼11.7, 4.7 Hz, H-60b); 13C NMR
(CDCl3) d (ppm): 166.0, 165.5, 165.1, 164.9, 159.5 (C]O, oxadiazole
C-2, C-5), 141.3 (C-10), 134.7e120.3 (aromatics), 102.7 (C-20), 75.1,
67.1, 66.5 (C-30eC-50), 61.2 (C-60). MS-ESI (m/z, positive mode):
Calcd for C39H29N2O8þ [MþH]þ: 653.2. Found: 653.1.
3.9.19. 5-(20-Deoxy-D-arabino-hex-10-enopyranosyl)-2-methyl-
1,3,4-oxadiazole (48)
Prepared from compound 45 (0.21 g, 0.38 mmol) according to
General procedure V (Section 3.6). Reaction time: 15 min. Puriﬁed
by column chromatography (9:1 CHCl3eMeOH) to yield 0.08 g
(90%) white solid. Mp: 154e155 C; [a]D 8 (c 0.50, DMSO); 1H
NMR (CD3OD) d (ppm): 5.79 (1H, d, J¼3.1 Hz, H-20), 4.31 (1H, dd,
J¼7.0, 3.1 Hz, H-30), 4.02e3.96 (2H, m, H-50, H-60a), 3.88 (1H, dd,
J¼11.7, 6.3 Hz, H-60b), 3.69 (1H, dd, J¼9.3, 7.0 Hz, H-40), 2.57 (3H, s,
CH3); 13C NMR (CD3OD) d (ppm): 166.1, 162.0 (oxadiazole C-2, C-5),
140.2 (C-10), 110.2 (C-20), 82.0, 70.2, 69.9 (C-30eC-50), 62.1 (C-60),
10.7 (CH3). MS-ESI (m/z, negative mode): Calcd for C11H15N2O7‒
[MþAcO]‒: 287.1. Found: 287.6.
3.9.20. 5-(20-Deoxy-D-arabino-hex-10-enopyranosyl)-2-phenyl-
1,3,4-oxadiazole (49)
Prepared from compound 46 (0.30 g, 0.50 mmol) according to
General procedure V (Section 3.6). Reaction time: 1 h. Puriﬁed by
column chromatography (9:1 CHCl3eMeOH) to yield 0.12 g (86%)hex-1-enopyranosyl)-oxadiazoles: synthesis of possible isomers and
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CAR6993_proof ■ 7 May 2015 ■ 9/9white solid. Mp: 193e194 C; [a]D þ8 (c 0.50, DMSO); 1H NMR
(DMSO-d6) d (ppm): 8.05 (2H, dd, J¼8.2, 1.4 Hz, aromatics),
7.67e7.59 (3H, m, aromatics), 5.89 (1H, d, J¼3.4 Hz, H-20), 5.41e5.37
(2H, 2OH), 4.81 (1H, OH), 4.19e4.15, 3.96e3.92, 3.85e3.80,
3.77e3.71, 3.62e3.57 (51H, 5m, H-30, H-40, H-50, H-60a, H-60b); 13C
NMR (DMSO-d6) d (ppm): 163.7, 159.9 (oxadiazole C-2, C-5), 138.2
(C-10), 129.6, 126.8, 126.5, 123.0 (aromatics), 110.1 (C-20), 81.01, 68.0,
67.9 (C-30eC-50), 59.7 (C-60). MS-ESI (m/z, negative mode): Calcd for
C16H17N2O7‒ [MþAcO]‒: 349.1. Found: 349.7.
3.9.21. 5-(20-Deoxy-D-arabino-hex-10-enopyranosyl)-2-(2-
naphthyl)-1,3,4-oxadiazole (50)
Prepared from compound 47 (0.20 g, 0.31 mmol) according to
General procedure V (Section 3.6). Reaction time: 1 h. Puriﬁed by
column chromatography (9:1 CHCl3eMeOH) to yield 0.08 g (77%)
white solid. Mp: decomposition above 174 C; [a]D þ18 (c 0.50,
DMSO); 1H NMR (DMSO-d6) d (ppm): 8.68 (1H, s, aromatic),
8.18e8.03 (4H, m, aromatics), 7.70e7.63 (2H, m, aromatics), 5.96
(1H, d, J¼2.7 Hz, H-20), 5.43e5.40 (2H, 2OH), 4.83 (1H, OH),
4.22e4.18, 3.99e3.95, 3.87e3.82, 3.78e3.74, 3.65e3.59 (51H, 5m,
H-30, H-40, H-50, H-60a, H-60b); 13C NMR (DMSO-d6) d (ppm): 163.9,
160.0 (oxadiazole C-2, C-5), 138.3 (C-10), 134.2, 132.4, 129.3, 129.0,
128.8, 128.1, 127.7, 127.2, 120.3 (aromatics), 110.2 (C-20), 81.0, 68.0,
67.9 (C-30eC-50), 59.7 (C-60). MS-ESI (m/z, positive mode): Calcd for
C18H17N2O5þ [MþH]þ: 341.1. Found: 341.3.
3.10. Enzyme assay
Glycogen phosphorylase b was prepared from rabbit skeletal
muscle according to the method of Fischer and Krebs,59 using
dithiothreitol instead of L-cysteine, and recrystallized at least three
times before use with a speciﬁc activity of 55 U/mg protein. Kinetic
experiments were performed in the direction of glycogen synthesis
as described previously.58 Kinetic data for the inhibition of rabbit
skeletal muscle glycogen phosphorylase were collected using 4mM
of a-D-glucose-1-phosphate constant concentrations of glycogen
(1% w/v) and AMP (1 mM), and various concentrations of inhibitor.
Inhibitor was dissolved in dimethyl sulfoxide (DMSO) and diluted
in the assay buffer (ﬁnal concentrations between 6.25 and 625 mM)
(50 mM triethanolamine, 100 mM KCl, 1 mM EDTA and 1 mM
dithiothreitol) so that the DMSO concentration in the assay should
be lower than 1%.
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